Agilent Partners with University of Michigan for Prostate Cancer Research
Agilent Technologies (Santa Clara, California) announced its support of prostate cancer research by the University of Michigan?s (Ann Arbor) Center for Translational Pathology through a grant of instruments and funding.
Agilent Technologies (Santa Clara, California) announced its support of prostate cancer research by the University of Michigan’s (Ann Arbor) Center for Translational Pathology through a grant of instruments and funding. The goal is to accelerate research to defeat the disease using a multidisciplinary systems biology approach. The company is contributing a 1200 Series liquid chromatography (LC) system to be used to separate metabolites from human plasma as well as a 1200 Series Rapid Resolution LC system coupled to a model 6530 Accurate Mass quadrupole time-of-flight mass spectrometer for the identification of those metabolites.
